Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of MHB018A in active moderate-to-severe thyroid eye disease
CTR20252346Phase 3Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Jun 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of MHB018A in Graves Orbitopathy (GO), sponsored by Minghui Pharmaceutical, Inc.. Started Jun 2025; status: active.
02
Drugs
MHB018A
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20252346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252346.